Sinan Can Taşan

Dr. Sinan Can Taşan

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2025 in Journal of Clinical and Translational Pathology
Verified
Journal Article
Open access
NÇNesibe Kahraman Çetin
Nesibe Kahraman Çetin
EÖEzgi Özkıran
Ezgi Özkıran
STSinan Can Taşan
Sinan Can Taşan
DADilara Akın
Dilara Akın
İEİbrahim Halil Erdoğdu
İbrahim Halil Erdoğdu
İMİbrahim Meteoglu
İbrahim Meteoglu
Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation sequencing (NGS), the disease is challenging to treat due to the limited number of detectable mutations for targeted drug therapy. This study aimed to evaluate the mutation profiles of LSCC detected by NGS to assess the relationships between different driver mutations and clinicopathological parameters.

Verified
Journal Article
Open access
PDF file
NÇNesibe Kahraman Çetin
Nesibe Kahraman Çetin
STSinan Can Taşan
Sinan Can Taşan
Nowadays, the aging human population exerts a notable influence on the treatment of thyroid diseases. The most appropriate approach for the treatment of benign and malignant thyroid diseases in older adults has not yet been determined. The aim of our study is to evaluate the effect of thyroidectomies in geriatric patients considering age, sex and histopathological parameters and to determine the importance of thyroidectomy as a treatment option in the geriatric population. A total of 910 cases from all age groups were included, for which thyroidectomies were examined and reported. In accordance with the College of American Pathologists Cancer Protocol for thyroid reporting, considering geriatric patients, the rate of Thyroid Follicular Nodular Disease was significantly higher among the tumor types in the benign tumor group (p = 0.033), while Anaplastic Thyroid Carcinoma rate was higher in the malignant tumor group. The diagnosis rate of malignant tumors was higher in males, reflecting a more advanced pT stage (p < 0.001), larger tumor size (p < 0.001) and increased lymph node involvement rate (p = 0.039). Given that increasing age is associated with a heightened incidence of thyroid disease, the safety of surgery for geriatric patients is an important issue. Thyroidectomy should be considered in the treatment of these patients, especially in males, as the rate of malignant diagnosis and worse histopathological parameters are seen with increasing age.

9 June 2025 in Egyptian Journal of Medical Human Genetics
Verified
Journal Article
Open access
PDF file
DADilara Akin
Dilara Akin
NÇNesibe Kahraman Çetin
Nesibe Kahraman Çetin
STSinan Can Taşan
Sinan Can Taşan
İEİbrahim Halil Erdoğdu
İbrahim Halil Erdoğdu
İMİbrahim Meteoglu
İbrahim Meteoglu
Background: Lymph node status is the most important prognostic factor in resectable non-small cell lung cancer (NSCLC). Considering the critical importance of lymph nodes, determining N status and related molecular biomarkers may contribute to the literature for understanding the pathogenesis in the early stage and shedding light on treatment. Materials and methods: 71 patients with lung adenocarcinoma and lymph node metastasis were included. Next-generation sequencing (NGS) was performed on metastatic lymph samples at the Molecular Pathology Laboratory of Aydın Adnan Menderes University Faculty of Medicine, Turkey. The gender, age, N Status and mutation results were analyzed. Results: Mutation was detected in 46 patients (69%). The most frequently observed mutations included Tumor Protein 53 (TP53) (17, 23.9%), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) (11, 15.5%), Epidermal Growth Factor Receptor (EGFR) (10, 14.1%), Phosphatase and tension homolog (PTEN) (9, 12.7%), Neurofibromatosis type 1 (NF1) (5, 7%) and B-Raf proto-oncogene, serine/threonine kinase (BRAF) (3, 4.2%). A statistically significant increase in mutation frequency was observed with advancing N stage (p < 0.01). Additionally, the number of patients with multiple mutation associations also increased with higher N stages. Although the increase in TP53, PTEN, and KRAS mutation rates with higher N stages did not reach statistical significance, a correlation was observed (p = 0.09, p = 0.07, and p = 0.06, respectively). Notably, KRAS G12C mutations were exclusively detected in advanced N stages. Conclusion: Our study reveals the mutation profile in lymph node metastases in different locations in patients with lung adenocarcinoma. We hope that this new information will contribute to the literature on early prevention of distant metastases.

30 September 2022 in TURKDERM
Verified
Journal Article
Open access
STSinan Can Taşan
Sinan Can Taşan
CTCanten Tataroğlu
Canten Tataroğlu
ESEkin Savk
Ekin Savk
FNFatma Nalbant
Fatma Nalbant

17 July 2026 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
HTHatice Telci
Hatice Telci
SASabin Goktas Aydin
Sabin Goktas Aydin
TETaskın Erkinuresin
Taskın Erkinuresin
STSinan Can Taşan
Sinan Can Taşan
EOEnes Ozluk
Enes Ozluk
ESErkan Somuncu
Erkan Somuncu
Total neoadjuvant therapy (TNT) has become an important treatment strategy for locally advanced rectal cancer (LARC), increasing the need for pretreatment biomarkers that may predict major tumor response and support organ-preserving approaches. This study aimed to evaluate whether pretreatment stromal CD4⁺ and CD8⁺ T-cell densities, together with stromal tumor-infiltrating lymphocytes (TILs), are associated with response to TNT in patients with LARC. In this retrospective study, 45 patients with LARC who completed TNT were analyzed; pretreatment colonoscopic biopsy specimens were available for all patients, and paired post-treatment resection specimens were available for 40 surgically treated patients. CD4⁺ and CD8⁺ T-cell densities were assessed immunohistochemically in stromal hotspot areas and expressed as cells/mm², while stromal TILs were evaluated on hematoxylin–eosin sections. A favorable response was defined as tumor regression grade (TRG) 0–1 in surgically treated patients or clinical complete response in patients managed with a watch-and-wait strategy. Median pretreatment CD4⁺ T-cell density, CD8⁺ T-cell density, and stromal TIL percentage were 320 cells/mm², 64 cells/mm², and 30%, respectively. Receiver operating characteristic (ROC) analysis identified a pretreatment stromal CD4⁺ T-cell density cutoff of 410 cells/mm² for favorable response, with an area under the curve (AUC) of 0.68 (p=0.041). CD4⁺ T-cell density >410 cells/mm² was significantly associated with favorable response and remained independently associated with response in multivariable logistic regression analysis (odds ratio [OR]=5.05, 95% confidence interval [CI]: 1.21–20.83, p=0.026). In contrast, pretreatment CD8⁺ T-cell density and stromal TIL percentage were not significantly associated with response. In paired specimens, CD8⁺ T-cell density increased significantly after treatment (p<0.001), whereas CD4⁺ T-cell density and stromal TIL percentage did not change significantly. Lymphovascular invasion (LVI) and perineural invasion (PNI) were associated with non-favorable response. High pretreatment stromal CD4⁺ T-cell density may represent a candidate biomarker of favorable response to TNT in LARC, while the post-treatment increase in CD8⁺ T-cell density suggests a potential immunomodulatory effect of TNT; however, prospective validation in larger cohorts is required.